GW & Wade’s Larimar Therapeutics LRMR Stock Holding History

GW & Wade’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,667	Closed	-$70K	–	243
2017 Q2	$70K	Hold	1,667	–	–	0.01%	232
2017 Q1	$93K	Hold	1,667	–	–	0.01%	236
2016 Q4	$64K	Buy	+1,667	New	+$67.6K	0.01%	221

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

GW & Wade's LRMR Position: Q3 2017 in Review

GW & Wade sold out of Larimar Therapeutics (LRMR) in Q3 2017, closing a stake of 1,667 shares — an estimated $70K sold.

GW & Wade first reported a position in LRMR in Q4 2016 and held it in 3 quarters. The position peaked at $93K in Q1 2017. 62 funds tracked by Wall St. Rank hold LRMR as of Q3 2017.

GW & Wade reported no remaining Larimar Therapeutics position as of Q3 2017 after selling out during the quarter.
GW & Wade sold 1,667 Larimar Therapeutics shares in Q3 2017, an estimated $70K.
GW & Wade first reported a position in Larimar Therapeutics in Q4 2016 and held it in 3 quarters.
GW & Wade's Larimar Therapeutics position peaked at $93K in Q1 2017.
62 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2017.

Based on GW & Wade's 13F filing for Q3 2017, filed 9 Nov 2017.